Abstract
Background: Most cancer cells rely on aerobic glycolysis. Dichloroacetate (DCA) inhibits aerobic glycolysis and is a promising relatively nontoxic anticancer compound. However, rapidly proliferating effector T-cells also rely on aerobic glycolysis, whereas regulatory T-cells (Treg) do not. The effect of DCA on glucose metabolism and Treg differentiation was evaluated in alloreactive lymphocytes.
Methods: Peripheral blood mononuclear cells from healthy volunteers were used in a two-way mixed lymphocyte reaction. Lymphocyte proliferation was assessed by cell counting; DCA cytotoxicity, by lactate dehydrogenase release assay; and glucose uptake and aerobic glycolysis, by measuring in the supernatants the correspondent glucose and lactate concentrations. Interleukin-10 (IL-10) was measured in the supernatants, whereas the Treg signature transcription factor forkhead box P3 (FOXP3) was measured in cell lysates by means of enzyme-linked immunosorbent assay.
Results: DCA had a minor effect on lymphocyte proliferation and cytotoxicity. However, DCA decreased glucose uptake and inhibited aerobic glycolysis. Finally, DCA markedly increased the production of IL-10 and the expression of FOXP3.
Conclusions: DCA inhibits aerobic glycolysis and induces Treg differentiation in human alloreactive lymphocytes. This could result in decreased immunosurveillance in case of its use as an anticancer drug. However, DCA could play a role as an immunosuppressant in the fields of transplantation and autoimmunity.
References
1. Warburg O. On the origin of cancer cells. Science 1956;123: 309–14.10.1126/science.123.3191.309Search in Google Scholar
2. Michelakis ED, Sutendra G, Dromparis P, Webster L, Haromy A, Niven E, et al. Metabolic modulation of glioblastoma with dichloroacetate. Sci Transl Med 2010;2:31ra4.10.1126/scitranslmed.3000677Search in Google Scholar
3. Stacpoole PW. The pharmacology of dichloroacetate. Metabolism 1989;38:1124–44.10.1016/0026-0495(89)90051-6Search in Google Scholar
4. Gerriets VA, Rathmell JC. Metabolic pathways in T cell fate and function. Trends Immunol 2012;33:168–73.10.1016/j.it.2012.01.010Search in Google Scholar PubMed PubMed Central
5. Maciver NJ, Jacobs SR, Wieman HL, Wofford JA, Coloff JL, Rathmell JC. Glucose metabolism in lymphocytes is a regulated process with significant effects on immune cell function and survival. J Leukocyte Biol 2008;84:949–57.10.1189/jlb.0108024Search in Google Scholar PubMed PubMed Central
6. Fox CJ, Hammerman PS, Thompson CB. Fuel feeds function: energy metabolism and the T-cell response. Nat Rev Immunol 2005;5:844–52.10.1038/nri1710Search in Google Scholar PubMed
7. Michalek RD, Gerriets VA, Jacobs SR, Macintyre AN, MacIver NJ, Mason EF, et al. Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. J Immunol 2011;186:3299–303.10.4049/jimmunol.1003613Search in Google Scholar PubMed PubMed Central
8. Shi LZ, Wang R, Huang G, Vogel P, Neale G, Green DR, et al. HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J Exp Med 2011;208:1367–76.10.1084/jem.20110278Search in Google Scholar PubMed PubMed Central
9. Eleftheriadis T, Pissas G, Karioti A, Antoniadi G, Liakopoulos V, Dafopoulou K, et al. The indoleamine 2,3-dioxygenase inhibitor 1-methyl-tryptophan suppresses mitochondrial function, induces aerobic glycolysis and decreases interleukin-10 production in human lymphocytes. Immunol Invest 2012;41:507–20.10.3109/08820139.2012.682244Search in Google Scholar PubMed
10. Bian L, Josefsson E, Jonsson IM, Verdrengh M, Ohlsson C, Bokarewa M, et al. Dichloroacetate alleviates development of collagen II-induced arthritis in female DBA/1 mice. Arthritis Res Ther 2009;11:R132. doi: 10.1186/ar2799.10.1186/ar2799Search in Google Scholar PubMed PubMed Central
11. Ostroukhova M, Goplen N, Karim MZ, Michalec L, Guo L, Liang Q, et al. The role of low-level lactate production in airway inflammation in asthma. Am J Physiol Lung Cell Mol Physiol 2012;302:L300–7.10.1152/ajplung.00221.2011Search in Google Scholar PubMed PubMed Central
12. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell 2008;133:775–87.10.1016/j.cell.2008.05.009Search in Google Scholar PubMed
13. Sakaguchi S, Miyara M, Costantino CM, Hafler DA. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 2010;10:490–500.10.1038/nri2785Search in Google Scholar PubMed
14. Sato T, Deiwick A, Raddatz G, Koyama K, Schlitt HJ. Interactions of allogeneic human mononuclear cells in the two-way mixed leucocyte culture (MLC): influence of cell numbers, subpopulations and cyclosporin. Clin Exp Immunol 1999;115:301–8.10.1046/j.1365-2249.1999.00784.xSearch in Google Scholar PubMed PubMed Central
15. Stacpoole PW, Kurtz TL, Han Z, Langaee T. Role of dichloroacetate in the treatment of genetic mitochondrial diseases. Adv Drug Delivery Rev 2008;60:1478–87.10.1016/j.addr.2008.02.014Search in Google Scholar PubMed PubMed Central
16. Bowker-Kinley MM, Davis WI, Wu P, Harris RA, Popov KM. Evidence for existence of tissue-specific regulation of the mammalian pyruvate dehydrogenase complex. Biochem J 1998;329(Pt 1):191–6.10.1042/bj3290191Search in Google Scholar PubMed PubMed Central
17. Couper KN, Blount DG, Riley EM. IL-10: the master regulator of immunity to infection. J Immunol 2008;180:5771–7.10.4049/jimmunol.180.9.5771Search in Google Scholar PubMed
18. Chaudhry A, Samstein RM, Treuting P, Liang Y, Pils MC, Heinrich JM, et al. Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. Immunity 2011;34:566–78.10.1016/j.immuni.2011.03.018Search in Google Scholar PubMed PubMed Central
19. Rubtsov YP, Rasmussen JP, Chi EY, Fontenot J, Castelli L, Ye X, et al. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity 2008;28:546–58.10.1016/j.immuni.2008.02.017Search in Google Scholar PubMed
20. Sabat R, Grutz G, Warszawska K, Kirsch S, Witte E, Wolk K, et al. Biology of interleukin-10. Cytokine Growth Factor Rev 2010;21:331–44.10.1016/j.cytogfr.2010.09.002Search in Google Scholar PubMed
©2013 by Walter de Gruyter Berlin Boston
